Literature DB >> 2553013

Solubilization and identification of human placental endothelin receptor.

S Nakajo1, M Sugiura, R M Snajdar, F H Boehm, T Inagami.   

Abstract

Endothelin-1 (ET-1) receptor was identified on the membranes from human placenta and 66% of original binding activity in the membranes was solubilized with 0.75% (w/v) CHAPS. Binding studies of the solubilized membranes using 125I-ET-1 indicated the presence of a single class of high-affinity binding sites with an apparent Kd of 760 pM and a Bmax of 1.8 pmol/mg of protein. The binding was inhibited by addition of unlabeled ET-1 and ET-3 in dose dependent manner. The Ki values of solubilized membranes were 84 pM for ET-1 and 250 pM for ET-3, whereas particulate membranes had weaker affinities (Ki = 410 pM for ET-1, 2500 pM for ET-3). Calcium channel blockers such as nicardipine, verapamil and diltiazem did not affect the binding of 125I-ET-1. Affinity labeling of the particulate and solubilized membranes with CHAPS revealed a specific binding protein with a Mr of 32,000.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2553013     DOI: 10.1016/0006-291x(89)91703-8

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  Differential localization of endothelin ETA and ETB binding sites in human placenta.

Authors:  R A Rutherford; J Wharton; A McCarthy; L Gordon; M H Sullivan; M G Elder; J M Polak
Journal:  Br J Pharmacol       Date:  1993-06       Impact factor: 8.739

2.  Hepatic effects of endothelin. Receptor characterization and endothelin-induced signal transduction in hepatocytes.

Authors:  C R Gandhi; R H Behal; S A Harvey; T A Nouchi; M S Olson
Journal:  Biochem J       Date:  1992-11-01       Impact factor: 3.857

3.  Endothelin as an autocrine factor in the regulation of parathyroid cells.

Authors:  Y Fujii; J E Moreira; C Orlando; M Maggi; G D Aurbach; M L Brandi; K Sakaguchi
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.